Find clear answers about peptides.
Search a peptide or question. Read what the evidence supports, where it stops, and what remains unknown.
New to peptides? Start with the basics34 peptide reviews · 137 fact checks
Is it approved? Is it banned in sport?
Quick status for the peptides people ask about most. FDA and sports status come from each peptide's review, reviewed through . Compounding means a pharmacy mixes a drug. The compounding column copies an FDA page dated .
| Peptide | FDA status | FDA compounding list | Sports rules |
|---|---|---|---|
| RetatrutideAlso: RETA, LY3437943 | No FDA-approved product | Not named on this FDA page | Not assessed |
| Semaglutide | FDA-approved productOzempic, Wegovy, Wegovy HD, Rybelsus | Not named on this FDA page | No prohibition identifiedChecked |
| Tirzepatide | FDA-approved productMounjaro, Zepbound | Not named on this FDA page | Not assessed |
| BPC-157Also: BPC 157, Body Protection Compound 157 | No FDA-approved product | Nomination withdrawn | ProhibitedChecked |
| TB-500Also: TB500, Ac-LKKTETQ | No FDA-approved product | Nomination withdrawnListed as thymosin beta-4, fragment (LKKTETQ), also known as TB-500. | ProhibitedChecked |
| IpamorelinAlso: ipamorelin acetate, NNC 26-0161 | No FDA-approved product | Category 2: safety riskListed as ipamorelin acetate under the 503B policy. A separate nomination was withdrawn. | ProhibitedChecked |
| CJC-1295Also: CJC 1295, CJC-1295 DAC | No FDA-approved product | Nomination withdrawn | ProhibitedChecked |
| Tesamorelin | FDA-approved productEgrifta SV, Egrifta WR | Not named on this FDA page | ProhibitedChecked |
An FDA approval covers the named products only, not every product sold under the same name.
What these labels mean
- Not named on this FDA page
- This FDA page does not name it. That does not show that a pharmacy may compound it. Other FDA lists and conditions still apply.
- Nomination withdrawn
- FDA had placed it in Category 2 for possible safety risks. The person who asked FDA to allow it in compounding then withdrew the request. FDA still lists its safety concerns and has not made a final decision. A withdrawn request is neither a ban nor an approval.
- Category 2: safety risk
- FDA placed it here because it may present significant safety risks in compounding, pending further review. Each entry names the policy it falls under: 503A covers pharmacies, and 503B covers outsourcing facilities.
- Not assessed
- We have no sports-rule review for it yet. That does not mean it is allowed.
- No prohibition identified
- This review did not find a prohibition in the checked record. This does not clear you to compete.
- Prohibited
- The checked rules list this substance or group as prohibited under the stated conditions. Check the current rules for your sport.
Peptide fact checks.
Explore a question.
Browse peptides.
Tirzepatide is the active ingredient in Mounjaro and Zepbound. Each approved product has its own uses and safety information. An approval for one product does not automatically apply to the other.
This review covers Ozempic, Rybelsus, Wegovy, and the Wegovy HD strength. Their forms, approved uses, and labels differ.
Still being studied. Late-stage study reports show meaningful results in people, but no product is approved and no regulatory review is complete.
Cell and animal studies, plus small early studies in people, do not prove that BPC-157 heals injuries in people.
How fact checks work.
Each fact check covers one statement and one situation. A molecule, an approved product, and an online product may not have the same evidence.
- The statement
“RETA’s results mean it is basically approved.”
- What the sources showSeveral late-stage trial resultsEarly results reported by the sponsorFoundAn FDA-approved productNone for retatrutide yetNot yet
- The answerThe sponsor reported large average weight reductions in late-stage trials.
Retatrutide is still being studied. It is not approved.
The trial shows what happened in that study. It does not by itself prove approval or that products sold online match the product studied.
Read the retatrutide review